Uninvited Guests in the Well: Recognising and Managing Antibody Interference in UK Immunoassays
An immunoassay result looks reassuringly precise: a number, a unit, a reference interval. Yet the number is the end of a complicated binding event, and the sample is not a neutral passenger. In UK diagnostic laboratories, unexplained results are still too readily attributed to calibration drift, reagent variability or an instrument fault. Sometimes the sample itself is the source of the problem. Rheumatoid factor, heterophile antibodies, human anti-mouse antibodies and related binding proteins can distort both sandwich and competitive immunoassays, producing results that are falsely high, falsely low or simply incompatible with the clinical picture.
The challenge is not that these interferents are unknown. It is that they are inconsistent, sample-specific and easy to overlook in a high-throughput workflow. A datasheet may promise that a blocking reagent reduces interference, but the laboratory still has to decide whether that promise holds for its own assay, its own population and its own reporting rules. In 2026, with UK laboratories under continued pressure to deliver faster turnaround while maintaining ISO 15189 accreditation, interference investigation needs to be a practical routine rather than an occasional troubleshooting exercise.
Where the interference begins
Rheumatoid factor is the best-known offender. These autoantibodies, usually directed against the Fc region of immunoglobulin G, can bridge capture and detection antibodies in a sandwich assay. The result is a signal that resembles analyte binding but is actually antibody-to-antibody binding. Rheumatoid factor is common in patients with rheumatoid arthritis, but it can also appear in other inflammatory and infectious conditions, and at low levels in some healthy individuals. It is therefore unwise to assume that only a known rheumatology sample is at risk.
Heterophile antibodies are weaker, multispecific antibodies that can bind immunoglobulins from other species. They may arise after animal exposure, vaccination, transfusion or infection, and they are often present without any obvious history. Human anti-mouse antibodies are a subset of particular relevance to assays that use murine monoclonal antibodies. Anti-drug antibodies in patients receiving therapeutic monoclonal antibodies can also interfere with assays that measure the drug or its downstream biomarkers. The precise label matters less than the behaviour: an antibody in the sample binds an assay component and changes the signal.
Other sample factors can mimic antibody interference even when no interfering antibody is present. Fibrin strands, complement activity, haemolysis, lipaemia, icterus and high analyte concentrations can all affect recovery or detection. Endogenous biotin is a separate but important issue for streptavidin-biotin formats. The practical lesson is that interference investigation should begin with sample quality and assay format, not with a reflex assumption that the patient has heterophile antibodies.
How it surfaces in routine and automated workflows
The first clue is often discordance. A result may be markedly higher or lower than expected from the clinical details, previous results or other laboratory findings. Delta checks and middleware rules can help, but they only work if the laboratory has defined what counts as unusual for the assay and the clinical context. A result that is plausible on its own can still be wrong if it fails to fit the patient.
Dilution behaviour is another useful signal. True analyte should usually dilute in a linear or predictable way when the assay is appropriately validated. Interfering antibodies may produce non-linear results, unusual recovery or a persistent signal at high dilution. Spike recovery experiments, in which a known amount of analyte is added to the sample, can reveal a matrix effect. Cross-platform comparison is valuable where an alternative method exists, although two assays can share the same interference mechanism and agree with each other for the wrong reason.
Automated systems bring particular risks. On-board dilution, repeat testing and autoverification can conceal the original problem or generate a result that looks more robust than it is. Laboratory staff should be able to see when a result has been diluted, repeated or flagged, and should have a route to pause reporting when the pattern is suspicious. The audit trail is part of the investigation, not an afterthought.
A practical interference checklist for UK laboratories
A useful checklist is not a substitute for scientific judgement, but it prevents the same steps being reinvented under time pressure. The following sequence is proportionate for suspected antibody interference in a UK diagnostic laboratory.
- Check sample integrity and pre-analytical history. Look for haemolysis, lipaemia, fibrin, delayed separation, inappropriate tube type or storage conditions.
- Compare the result with previous results, clinical details and other analytes. A single abnormal value is weaker evidence than a discordant pattern.
- Review the assay format. Is it a sandwich assay using murine antibodies, a competitive format, or a streptavidin-biotin system? Which species and antibody fragments are involved?
- Perform serial dilution in the validated diluent and assess linearity and recovery. Do not assume that dilution alone proves or excludes interference.
- Test with a heterophile blocking reagent or non-immune animal serum where the assay format and validation support it. Include a control sample to detect non-specific effects from the blocker itself.
- Re-test on an alternative platform or with an orthogonal method if available. Consider whether the alternative method measures the same analyte form and has its own interference profile.
- Consider rheumatoid factor testing only where it is clinically and analytically justified. A positive rheumatoid factor result supports the investigation but does not confirm that the assay result is false.
- Document the findings, the action taken and the reporting decision. If the result cannot be resolved, report with an appropriate caveat and recommend clinical liaison or repeat sampling.
Blocking strategies and design choices
Blocking reagents can be effective, but they are not universal antidotes. Non-immune sera, commercially available heterophile blocking reagents, Fab fragments and modified capture antibodies can reduce certain interactions. The choice depends on the assay format, the species of the antibodies and the source of the interference. A blocker that works well in one sample may be ineffective in another, and some blockers can introduce matrix effects or dilute the analyte signal.
Assay design offers more durable protection. Recombinant antibodies, F(ab')2 fragments, non-murine antibody pairs and formats that avoid vulnerable Fc interactions can reduce the opportunity for interference. Where streptavidin-biotin chemistry is used, biotin interference should be assessed separately. Validation should include samples with known rheumatoid factor, heterophile antibodies and relevant clinical backgrounds where feasible, not only pooled sera from convenient donors. The aim is not to eliminate every theoretical interference, but to understand the assay's vulnerabilities and to validate the checks that will be used when suspicion arises.
Confirmation is a process, not a single test
No single confirmatory test resolves all interference. A blocking reagent may reduce a signal, but that does not prove the original result was false. A dilution may be linear in one sample and misleading in another. The strongest conclusion comes from a consistent body of evidence: discordant clinical findings, non-linear dilution, recovery failure, a plausible assay mechanism and a supportive alternative method. Where uncertainty remains, the laboratory should say so clearly and avoid overstating precision.
For UK laboratories, the governance framework matters as much as the technical steps. Standard operating procedures should define who investigates suspected interference, which checks are authorised, how results are communicated and how incidents are reviewed. ISO 15189 accreditation expectations, UK NEQAS performance monitoring and local quality management systems all support a consistent approach. The sample may be an uninvited guest in the well, but the laboratory can still set the rules of engagement.
